Cargando…
Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in childhood and the reason for chronic renal replacement therapy. It leads to significant morbidity and mortality during the acute phase. In addition to acute morbidity and mortality, long-term renal and extrarenal comp...
Autores principales: | Scheiring, Johanna, Andreoli, Sharon P., Zimmerhackl, Lothar Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901419/ https://www.ncbi.nlm.nih.gov/pubmed/18704506 http://dx.doi.org/10.1007/s00467-008-0935-6 |
Ejemplares similares
-
Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?
por: Bielaszewska, Martina, et al.
Publicado: (2007) -
Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)
por: Loos, Sebastian, et al.
Publicado: (2021) -
An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019) -
Shiga Toxins and the Pathophysiology of Hemolytic Uremic Syndrome in Humans and Animals
por: Mayer, Chad L., et al.
Publicado: (2012) -
Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)